Seromycin Related Published Studies
Well-designed clinical trials related to Seromycin (Cycloserine)
A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. [2008.03.15]
Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. [2008.03]
D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. [2007.10.15]
A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. [2007.09]
D-Cycloserine and performance under different states of anxiety in healthy volunteers. [2007.09]
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. [2007.07]
A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. [2007.04]
A randomized controlled trial of the effect of d-cycloserine on extinction and fear conditioning in humans. [2006.09.06]
A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. [2006.07.07]
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. [2006.03]
A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. [2005.04]
Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. [2005.01.30]
Effects of D-cycloserine on negative symptoms in schizophrenia. [2004.12.01]
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. [2004.11]
Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. [2002.12]
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. [2002.03]
Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. [2001.08]
Bioequivalence assessment of closerin capsule to dura seromycin capsule of cycloserine after a single oral dose administration to healthy male volunteers. [2000.10]
IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. [2000.03.01]
Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. [1999.03]
A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. [1999.02.15]
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. [1999.01]
The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. [1998.07]
A preliminary study of D-cycloserine treatment in Alzheimer's disease. [1998.03]
Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. [1997.05]
D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. [1996.10]
Evaluation of cycloserine in the treatment of Alzheimer's disease. [1995.10]
Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. [1995.02]
D-cycloserine treatment of Alzheimer disease. [1994.09]
Well-designed clinical trials possibly related to Seromycin (Cycloserine)
Limited impact of homeostatic plasticity on motor learning in humans. [2008]
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. [2006.09.15]
D-alanine added to antipsychotics for the treatment of schizophrenia. [2006.02.01]
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. [2005.11]
Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. [2005.08]
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. [2004.03.01]
Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. [2004]
Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. [2001.11]
Placebo-controlled trial of glycine added to clozapine in schizophrenia. [2000.05]
D-serine added to clozapine for the treatment of schizophrenia. [1999.11]
Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex. [1990.04]
Other research related to Seromycin (Cycloserine)
Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study. [2008.09.15]
Facilitation of extinction of operant behaviour in mice by D: -cycloserine. [2008.09.11]
Effects of single prolonged stress and D-cycloserine on contextual fear extinction and hippocampal NMDA receptor expression in a rat model of PTSD. [2008.08]
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. [2008.06.15]
A Meta-Analysis of D-Cycloserine and the Facilitation of Fear Extinction and Exposure Therapy. [2008.02.28]
Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors. [2008.01]
[A case of multi-drug resistant tuberculosis showing psychiatric adverse effect by cycloserine] [2008.01]
D-cycloserine reduces neuropathic pain behavior through limbic NMDA-mediated circuitry. [2007.11]
NMDA receptor modulation by D-cycloserine promotes episodic-like memory in mice. [2007.09]
D-cycloserine inhibits amygdala responses during repeated presentations of faces. [2007.08]
The Application of Exposure Therapy and D-Cycloserine to the Treatment of Anorexia Nervosa: A Preliminary Trial. [2007.07]
D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. [2007.07]
Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex. [2007.07]
Intrathecally administered D-cycloserine produces nociceptive behavior through the activation of N-methyl-D-aspartate receptor ion-channel complex acting on the glycine recognition site. [2007.05]
Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. [2007.01]
Delay aversion: effects of 7-OH-DPAT, 5-HT1A/1B-receptor stimulation and D-cycloserine. [2006.12]
Influence of ethanol withdrawal on fear memory: Effect of D-cycloserine. [2006.11.03]
Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. [2006.09]
Effects of D-cycloserine on extinction: translation from preclinical to clinical work. [2006.08.15]
Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. [2006.07]
Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. [2005.05]
A pilot study of D-cycloserine in subjects with autistic disorder. [2004.11]
Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. [2004.09]
D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. [2004.06]
Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia. [2004.04.09]
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. [2004.02.01]
Substrate reduction intervention by L-cycloserine in twitcher mice (globoid cell leukodystrophy) on a B6;CAST/Ei background. [2003.08.14]
D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure. [2003.08]
D-cycloserine for the treatment of ataxia in spinocerebellar degeneration. [2003.06.15]
D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. [2002.07.01]
Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. [2002.03.15]
D-cycloserine for Alzheimer's disease. [2002]
L-cycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice). [2000.04.15]
Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. [2000.03.31]
D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. [1999.08]
Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation. [1999.01.29]
The stereo-specific effect of D-serine ethylester and the D-cycloserine in ataxic mutant mice. [1998.10.12]
Cycloserine-induced decrease of cerebroside in myelin. [1998.04]
Infusion of D-cycloserine into temporal-hippocampal areas and restoration of mnemonic function in rats with disrupted glutamatergic temporal systems. [1997.06.05]
Cycloserine-induced Stevens-Johnson syndrome in an AIDS patient with multidrug-resistant tuberculosis. [1997.04]
D-cycloserine added to clozapine for patients with schizophrenia. [1996.12]
Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury. [1996.11.25]
Influence of D-cycloserine on the anticonvulsant activity of phenytoin and carbamazepine against electroconvulsions in mice. [1996.07]
d-Cycloserine enhances implicit memory in Alzheimer patients. [1996.02]
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. [1995.08]
[Ofloxacin-cycloserine-protionamide-INH combination against treatment refractory lung tuberculosis] [1995.02]
Effect of the glycine/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice. [1994.05.23]
Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. [1994.05.12]
Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats. [1994.05]
d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. [1994]
The glycine/NMDA receptor ligand (+)-HA-966 but not D-cycloserine has potent antidystonic efficacy in a genetic animal model of dystonia. [1993.08.03]
The anticonvulsant activity of D-cycloserine is specific for tonic convulsions. [1993.06]
7-Chlorokynurenic acid antagonizes the anticonvulsant activity of D-cycloserine in maximal electroshock seizures. [1992.10]
Failure of d-cycloserine to reverse cognitive disruption induced by scopolamine or phencyclidine in primates. [1992]
The long-term administration of L-cycloserine to mice: specific reduction of cerebroside level. [1989.03]
Inhibition of serine palmitoyltransferase activity in rabbit aorta by L-cycloserine. [1987.12]
Other possibly related research studies
An ionotropic but not a metabotropic glutamate agonist potentiates the pharmacological effects of olanzapine in the rat. [2005.12]
Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. [2005.11]
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia. [2005.09.08]
Genomic fingerprinting of antituberculosis agents-resistant Lactobacillus ruminus SPM0211 using the Microbial Uniprimer kit. [2005.07]
Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. [2005]
|
